Vaccine maker BioNTech reports potential multiple sclerosis breakthrough


BioNTech, the German biotechnology company that paired with Pfizer to develop the first COVID-19 vaccine approved in the U.S., reports in the journal Science that a new vaccine using the same mRNA technique has proved effective in treating or stopping multiple sclerosis in lab mice. MS is caused not by a virus but by the immune system malfunctioning and attacking the protective covering of nerve cells in the brain and spinal cord, disrupting signals between those cells and their targets in the body, causing neurological, sensory, and motor issues.
BioNTech said it successfully encoded MS-specific autoantigens that, when delivered via its experimental vaccine, stopped MS symptoms in mice bred with a condition mirroring MS in humans, and prevented further deterioration in mice with early signs of MS. Mice given a placebo showed typical MS symptoms.
Existing MS treatments "work by systemically suppressing the immune system," Angus Liu writes in Fierce Biotech. "That can control MS, but it also leaves patients vulnerable to infections." BioNTech's vaccine did not compromise normal immune function. The researchers said their findings suggest that mRNA vaccines, which can be developed quickly, could soon be used to treat "disease-causing antigens of individual patients."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
How will the new Repayment Assistance Plan for student loans work?
the explainer The Repayment Assistance Plan (RAP) will replace existing income-driven repayment plans
-
In the Spotlight Venezuelan President Nicolás Maduro has been at odds with US forces
-
Music reviews: Ethel Cain, Amaarae, and The Black Keys
Feature "Willoughby Tucker, I'll Always Love You," "Black Star," and "No Rain, No Flowers"
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages